English

SYROS PHARMACEUTICALS, INC.

EDGAR

SYRS Quarterly report (10-Q) · filed 2024-10-31

48 filing records in this dataset, filed from 2016-06-03 to 2024-10-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

386 thousand USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 9936000 USD Source
Revenue: 9550000 USD Source

Operating margin

-7,031.09%

2023 Q4 · %

Exact inputs and evidence

Operating Income: -128988000 USD Source
Operating Income: -101848000 USD Source
Revenue: 9936000 USD Source
Revenue: 9550000 USD Source

Operating cash flow

-18.6 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -109707000 USD Source
Operating Cash Flow: -91145000 USD Source

Free cash flow

-18.6 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -109707000 USD Source
Operating Cash Flow: -91145000 USD Source
Capital Expenditure: 272000 USD Source
Capital Expenditure: 234000 USD Source

Cash and cash equivalents: 58.3 million USD 2024-09-30 Source
Exact value

58275000 USD
Long-term debt including current maturities: 40.5 million USD 2022-09-30 Source
Exact value

40514000 USD
Shares outstanding: 26.8 million shares 2024-09-30 Source
Exact value

26832457 shares

Reported share-count change

29.50% · 6.11 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

20720447 shares · 2023-09-30· Source
26832457 shares · 2024-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-10-31.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2023-12-31
Operating income: 8 of 11 periods available· newest 2023-12-31
Net income: 8 of 11 periods available· newest 2023-12-31
Operating cash flow: 8 of 11 periods available· newest 2023-12-31
Capital expenditure: 8 of 11 periods available· newest 2023-12-31
Total assets: 7 of 11 periods available· newest 2023-12-31
liabilities: No compatible figures in this window
Current assets: 7 of 11 periods available· newest 2023-12-31
Current liabilities: 7 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2021-12-31
Shares outstanding: 7 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-33.2%

Prior period

USD 14.88 million

2022-01-01 – 2022-12-31
Current period

USD 9.94 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

9936000 − 14880000 = -4944000 USD

14880000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
9936000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Year-over-year change in Revenue: -4944000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 9936000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1409281 Filing: 000095017024036808 Input fundies:Revenue: 14880000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1410524 Filing: 000095017024036808
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 69.9 million

Prior period

−USD 94.7 million

2022-01-01 – 2022-12-31
Current period

−USD 164.6 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-164600000 − -94700000 = -69900000 USD

-94700000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-164600000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Year-over-year change in Net income: -69900000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -164600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1818165 Filing: 000095017024036808 Input fundies:NetIncome: -94700000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1818664 Filing: 000095017024036808
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 13.36 million

Prior period

−USD 123.07 million

2022-01-01 – 2022-12-31
Current period

−USD 109.71 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-109707000 − -123065000 = 13358000 USD

-123065000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-109707000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Year-over-year change in Operating cash flow: 13358000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -109707000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1722225 Filing: 000095017024036808 Input fundies:OperatingCashFlow: -123065000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1723660 Filing: 000095017024036808
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-78.1%

Prior period

USD 1.24 million

2022-01-01 – 2022-12-31
Current period

USD 272,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

272000 − 1241000 = -969000 USD

1241000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
272000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Year-over-year change in Capital expenditure: -969000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 272000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1727223 Filing: 000095017024036808 Input fundies:CapitalExpenditure: 1241000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1728541 Filing: 000095017024036808
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 9.94 million 100% of revenue
Operating costs Derived USD 138.92 million 1,398% of revenue
Operating income −USD 128.99 million −1,298% of revenue
Tax, interest and other Derived USD 35.61 million 358% of revenue
Net income −USD 164.6 million −1,657% of revenue

Cash

Operating cash flow −USD 109.71 million −1,104% of revenue
Capital expenditure USD 272,000 2.7% of revenue
Free cash flow Derived −USD 109.98 million −1,107% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 15,230% of revenue.
2017 Operating loss: operating costs were 5,067% of revenue.
2018 Operating loss: operating costs were 3,162% of revenue.
2019 Operating loss: operating costs were 4,022% of revenue.
2020 Operating loss: operating costs were 645% of revenue.
2021 Operating loss: operating costs were 523% of revenue.
2022 Operating loss: operating costs were 1,013% of revenue.
2023 Operating loss: operating costs were 1,398% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	317000	48280000 Derived	-47963000	-263000 Derived	-47700000	-42858000 Derived	Source 2016-01-01 – 2016-12-31: 317000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -47963000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -47700000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -40536000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2322000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	1101000	55787000 Derived	-54686000	-686000 Derived	-54000000	-45550000 Derived	Source 2017-01-01 – 2017-12-31: 1101000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -54686000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -54000000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -44729000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 821000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	2100000	66396000 Derived	-64296000	-1996000 Derived	-62300000	-41699000 Derived	Source 2018-01-01 – 2018-12-31: 2100000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -64296000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -62300000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -40315000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1384000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1982000	79723000 Derived	-77741000	-2341000 Derived	-75400000	-72891000 Derived	Source 2019-01-01 – 2019-12-31: 1982000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -77741000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -75400000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -60253000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 12638000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	15093000	97390000 Derived	-82297000	1703000 Derived	-84000000	-60700000 Derived	Source 2020-01-01 – 2020-12-31: 15093000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -82297000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -84000000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -57364000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3336000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	23488000	122908000 Derived	-99420000	-12820000 Derived	-86600000	-100785000 Derived	Source 2021-01-01 – 2021-12-31: 23488000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -99420000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -86600000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -99540000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1245000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	14880000	150753000 Derived	-135873000	-41173000 Derived	-94700000	-124306000 Derived	Source 2022-01-01 – 2022-12-31: 14880000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -135873000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -94700000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -123065000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1241000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	9936000	138924000 Derived	-128988000	35612000 Derived	-164600000	-109979000 Derived	Source 2023-01-01 – 2023-12-31: 9936000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -128988000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -164600000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -109707000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 272000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 9.9M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	317000	Revenue: 317000 Open source
20172017-12-31	Revenue	1101000	Revenue: 1101000 Open source
20182018-12-31	Revenue	2100000	Revenue: 2100000 Open source
20192019-12-31	Revenue	1982000	Revenue: 1982000 Open source
20202020-12-31	Revenue	15093000	Revenue: 15093000 Open source
20212021-12-31	Revenue	23488000	Revenue: 23488000 Open source
20222022-12-31	Revenue	14880000	Revenue: 14880000 Open source
20232023-12-31	Revenue	9936000	Revenue: 9936000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-33.2% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 317000 Open source
20172017-12-31	Year over year	247.3%	Revenue: 1101000 Open source Revenue: 317000 Open source
20182018-12-31	Year over year	90.7%	Revenue: 2100000 Open source Revenue: 1101000 Open source
20192019-12-31	Year over year	-5.6%	Revenue: 1982000 Open source Revenue: 2100000 Open source
20202020-12-31	Year over year	661.5%	Revenue: 15093000 Open source Revenue: 1982000 Open source
20212021-12-31	Year over year	55.6%	Revenue: 23488000 Open source Revenue: 15093000 Open source
20222022-12-31	Year over year	-36.6%	Revenue: 14880000 Open source Revenue: 23488000 Open source
20232023-12-31	Year over year	-33.2%	Revenue: 9936000 Open source Revenue: 14880000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,298.2% 2023

Net margin -1,656.6% 2023

Free cash flow margin -1,106.9% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-15,130.3%	Operating Income: -47963000 Open source Revenue: 317000 Open source
20172017-12-31	Operating margin	-4,966.9%	Operating Income: -54686000 Open source Revenue: 1101000 Open source
20182018-12-31	Operating margin	-3,061.7%	Operating Income: -64296000 Open source Revenue: 2100000 Open source
20192019-12-31	Operating margin	-3,922.4%	Operating Income: -77741000 Open source Revenue: 1982000 Open source
20202020-12-31	Operating margin	-545.3%	Operating Income: -82297000 Open source Revenue: 15093000 Open source
20212021-12-31	Operating margin	-423.3%	Operating Income: -99420000 Open source Revenue: 23488000 Open source
20222022-12-31	Operating margin	-913.1%	Operating Income: -135873000 Open source Revenue: 14880000 Open source
20232023-12-31	Operating margin	-1,298.2%	Operating Income: -128988000 Open source Revenue: 9936000 Open source
20162016-12-31	Net margin	-15,047.3%	Net Income: -47700000 Open source Revenue: 317000 Open source
20172017-12-31	Net margin	-4,904.6%	Net Income: -54000000 Open source Revenue: 1101000 Open source
20182018-12-31	Net margin	-2,966.7%	Net Income: -62300000 Open source Revenue: 2100000 Open source
20192019-12-31	Net margin	-3,804.2%	Net Income: -75400000 Open source Revenue: 1982000 Open source
20202020-12-31	Net margin	-556.5%	Net Income: -84000000 Open source Revenue: 15093000 Open source
20212021-12-31	Net margin	-368.7%	Net Income: -86600000 Open source Revenue: 23488000 Open source
20222022-12-31	Net margin	-636.4%	Net Income: -94700000 Open source Revenue: 14880000 Open source
20232023-12-31	Net margin	-1,656.6%	Net Income: -164600000 Open source Revenue: 9936000 Open source
20162016-12-31	Free cash flow margin	-13,519.9%	Revenue: 317000 Open source Operating Cash Flow: -40536000 Open source Capital Expenditure: 2322000 Open source
20172017-12-31	Free cash flow margin	-4,137.1%	Revenue: 1101000 Open source Operating Cash Flow: -44729000 Open source Capital Expenditure: 821000 Open source
20182018-12-31	Free cash flow margin	-1,985.7%	Revenue: 2100000 Open source Operating Cash Flow: -40315000 Open source Capital Expenditure: 1384000 Open source
20192019-12-31	Free cash flow margin	-3,677.6%	Revenue: 1982000 Open source Operating Cash Flow: -60253000 Open source Capital Expenditure: 12638000 Open source
20202020-12-31	Free cash flow margin	-402.2%	Revenue: 15093000 Open source Operating Cash Flow: -57364000 Open source Capital Expenditure: 3336000 Open source
20212021-12-31	Free cash flow margin	-429.1%	Revenue: 23488000 Open source Operating Cash Flow: -99540000 Open source Capital Expenditure: 1245000 Open source
20222022-12-31	Free cash flow margin	-835.4%	Revenue: 14880000 Open source Operating Cash Flow: -123065000 Open source Capital Expenditure: 1241000 Open source
20232023-12-31	Free cash flow margin	-1,106.9%	Revenue: 9936000 Open source Operating Cash Flow: -109707000 Open source Capital Expenditure: 272000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -109.7M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-40536000	Operating Cash Flow: -40536000 Open source
20172017-12-31	Operating cash flow	-44729000	Operating Cash Flow: -44729000 Open source
20182018-12-31	Operating cash flow	-40315000	Operating Cash Flow: -40315000 Open source
20192019-12-31	Operating cash flow	-60253000	Operating Cash Flow: -60253000 Open source
20202020-12-31	Operating cash flow	-57364000	Operating Cash Flow: -57364000 Open source
20212021-12-31	Operating cash flow	-99540000	Operating Cash Flow: -99540000 Open source
20222022-12-31	Operating cash flow	-123065000	Operating Cash Flow: -123065000 Open source
20232023-12-31	Operating cash flow	-109707000	Operating Cash Flow: -109707000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -110M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-42858000	Operating Cash Flow: -40536000 Open source Capital Expenditure: 2322000 Open source
20172017-12-31	Free cash flow	-45550000	Operating Cash Flow: -44729000 Open source Capital Expenditure: 821000 Open source
20182018-12-31	Free cash flow	-41699000	Operating Cash Flow: -40315000 Open source Capital Expenditure: 1384000 Open source
20192019-12-31	Free cash flow	-72891000	Operating Cash Flow: -60253000 Open source Capital Expenditure: 12638000 Open source
20202020-12-31	Free cash flow	-60700000	Operating Cash Flow: -57364000 Open source Capital Expenditure: 3336000 Open source
20212021-12-31	Free cash flow	-100785000	Operating Cash Flow: -99540000 Open source Capital Expenditure: 1245000 Open source
20222022-12-31	Free cash flow	-124306000	Operating Cash Flow: -123065000 Open source Capital Expenditure: 1241000 Open source
20232023-12-31	Free cash flow	-109979000	Operating Cash Flow: -109707000 Open source Capital Expenditure: 272000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	Total Assets: 78488000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 106766000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 149978000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 213250000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 182935000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 244486000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 168174000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.95× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	5.89×	Current Assets: 73159000 Open source Current Liabilities: 12413000 Open source
20182018-12-31	Current assets / current liabilities	5.21×	Current Assets: 101734000 Open source Current Liabilities: 19529000 Open source
20192019-12-31	Current assets / current liabilities	4.87×	Current Assets: 114513000 Open source Current Liabilities: 23516000 Open source
20202020-12-31	Current assets / current liabilities	6.24×	Current Assets: 178557000 Open source Current Liabilities: 28624000 Open source
20212021-12-31	Current assets / current liabilities	4.33×	Current Assets: 136585000 Open source Current Liabilities: 31508000 Open source
20222022-12-31	Current assets / current liabilities	6.87×	Current Assets: 211392000 Open source Current Liabilities: 30778000 Open source
20232023-12-31	Current assets / current liabilities	3.95×	Current Assets: 144980000 Open source Current Liabilities: 36681000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 47.7 million Exact value Exact value: -47700000 USD 2016-01-01 – 2016-12-31: -47700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2016-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -47700000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47700000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459019042566/syrs-20190930.xml#1557362 Filing: 000156459019042566 The citation records this snapshot. The page link may show a newer release later.	−USD 40.54 million Exact value Exact value: -40536000 USD 2016-01-01 – 2016-12-31: -40536000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2016-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -40536000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40536000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/syrs-20181231.xml#163117 Filing: 000156459019006610 The citation records this snapshot. The page link may show a newer release later.	USD 2.32 million Exact value Exact value: 2322000 USD 2016-01-01 – 2016-12-31: 2322000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2016-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 2322000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2322000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/syrs-20181231.xml#163748 Filing: 000156459019006610 The citation records this snapshot. The page link may show a newer release later.	−USD 42.86 million Calculation and evidence -40536000 − 2322000 USD Exact free cash flow: -42858000 USD 2016-01-01 – 2016-12-31: -40536000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2322000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2016-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -42858000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40536000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/syrs-20181231.xml#163117 Filing: 000156459019006610 Input fundies:CapitalExpenditure: 2322000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/syrs-20181231.xml#163748 Filing: 000156459019006610 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 54 million Exact value Exact value: -54000000 USD 2017-01-01 – 2017-12-31: -54000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2017-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -54000000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54000000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459020051239/syrs-10q_20200930.htm#1276124 Filing: 000156459020051239 The citation records this snapshot. The page link may show a newer release later.	−USD 44.73 million Exact value Exact value: -44729000 USD 2017-01-01 – 2017-12-31: -44729000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2017-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -44729000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44729000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/syrs-20191231.xml#199181 Filing: 000156459020008795 The citation records this snapshot. The page link may show a newer release later.	USD 821,000 Exact value Exact value: 821000 USD 2017-01-01 – 2017-12-31: 821000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2017-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 821000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 821000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/syrs-20191231.xml#199814 Filing: 000156459020008795 The citation records this snapshot. The page link may show a newer release later.	−USD 45.55 million Calculation and evidence -44729000 − 821000 USD Exact free cash flow: -45550000 USD 2017-01-01 – 2017-12-31: -44729000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 821000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2017-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -45550000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44729000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/syrs-20191231.xml#199181 Filing: 000156459020008795 Input fundies:CapitalExpenditure: 821000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/syrs-20191231.xml#199814 Filing: 000156459020008795 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 62.3 million Exact value Exact value: -62300000 USD 2018-01-01 – 2018-12-31: -62300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2018-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -62300000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62300000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459021054726/syrs-10q_20210930.htm#1164369 Filing: 000156459021054726 The citation records this snapshot. The page link may show a newer release later.	−USD 40.32 million Exact value Exact value: -40315000 USD 2018-01-01 – 2018-12-31: -40315000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2018-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -40315000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40315000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459021010709/syrs-10k_20201231.htm#2741143 Filing: 000156459021010709 The citation records this snapshot. The page link may show a newer release later.	USD 1.38 million Exact value Exact value: 1384000 USD 2018-01-01 – 2018-12-31: 1384000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2018-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 1384000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1384000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459021010709/syrs-10k_20201231.htm#2751979 Filing: 000156459021010709 The citation records this snapshot. The page link may show a newer release later.	−USD 41.7 million Calculation and evidence -40315000 − 1384000 USD Exact free cash flow: -41699000 USD 2018-01-01 – 2018-12-31: -40315000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1384000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2018-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -41699000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40315000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459021010709/syrs-10k_20201231.htm#2741143 Filing: 000156459021010709 Input fundies:CapitalExpenditure: 1384000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000156459021010709/syrs-10k_20201231.htm#2751979 Filing: 000156459021010709 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 75.4 million Exact value Exact value: -75400000 USD 2019-01-01 – 2019-12-31: -75400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2019-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -75400000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75400000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017022024680/syrs-20220930.htm#1381896 Filing: 000095017022024680 The citation records this snapshot. The page link may show a newer release later.	−USD 60.25 million Exact value Exact value: -60253000 USD 2019-01-01 – 2019-12-31: -60253000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2019-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -60253000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -60253000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000119312522195811/d365321ds4.htm#7217285 Filing: 000119312522195811 The citation records this snapshot. The page link may show a newer release later.	USD 12.64 million Exact value Exact value: 12638000 USD 2019-01-01 – 2019-12-31: 12638000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2019-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 12638000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12638000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000119312522195811/d365321ds4.htm#7222504 Filing: 000119312522195811 The citation records this snapshot. The page link may show a newer release later.	−USD 72.89 million Calculation and evidence -60253000 − 12638000 USD Exact free cash flow: -72891000 USD 2019-01-01 – 2019-12-31: -60253000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 12638000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2019-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -72891000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -60253000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000119312522195811/d365321ds4.htm#7217285 Filing: 000119312522195811 Input fundies:CapitalExpenditure: 12638000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000119312522195811/d365321ds4.htm#7222504 Filing: 000119312522195811 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 84 million Exact value Exact value: -84000000 USD 2020-01-01 – 2020-12-31: -84000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2020-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -84000000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -84000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2945860 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	−USD 57.36 million Exact value Exact value: -57364000 USD 2020-01-01 – 2020-12-31: -57364000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2020-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -57364000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57364000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2730385 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	USD 3.34 million Exact value Exact value: 3336000 USD 2020-01-01 – 2020-12-31: 3336000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2020-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 3336000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3336000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2741693 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	−USD 60.7 million Calculation and evidence -57364000 − 3336000 USD Exact free cash flow: -60700000 USD 2020-01-01 – 2020-12-31: -57364000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3336000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2020-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -60700000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57364000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2730385 Filing: 000095017023005702 Input fundies:CapitalExpenditure: 3336000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2741693 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 86.6 million Exact value Exact value: -86600000 USD 2021-01-01 – 2021-12-31: -86600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2021-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -86600000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -86600000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2945146 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	−USD 99.54 million Exact value Exact value: -99540000 USD 2021-01-01 – 2021-12-31: -99540000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2021-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -99540000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -99540000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2728062 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	USD 1.25 million Exact value Exact value: 1245000 USD 2021-01-01 – 2021-12-31: 1245000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2021-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 1245000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1245000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2739509 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.	−USD 100.79 million Calculation and evidence -99540000 − 1245000 USD Exact free cash flow: -100785000 USD 2021-01-01 – 2021-12-31: -99540000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1245000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2021-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -100785000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -99540000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2728062 Filing: 000095017023005702 Input fundies:CapitalExpenditure: 1245000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017023005702/syrs-20221231.htm#2739509 Filing: 000095017023005702 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 94.7 million Exact value Exact value: -94700000 USD 2022-01-01 – 2022-12-31: -94700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2022-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -94700000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -94700000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1818664 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	−USD 123.07 million Exact value Exact value: -123065000 USD 2022-01-01 – 2022-12-31: -123065000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2022-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -123065000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -123065000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1723660 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1241000 USD 2022-01-01 – 2022-12-31: 1241000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2022-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 1241000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1241000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1728541 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	−USD 124.31 million Calculation and evidence -123065000 − 1241000 USD Exact free cash flow: -124306000 USD 2022-01-01 – 2022-12-31: -123065000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1241000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2022-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -124306000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -123065000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1723660 Filing: 000095017024036808 Input fundies:CapitalExpenditure: 1241000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1728541 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 164.6 million Exact value Exact value: -164600000 USD 2023-01-01 – 2023-12-31: -164600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Net Income: -164600000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -164600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1818165 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	−USD 109.71 million Exact value Exact value: -109707000 USD 2023-01-01 – 2023-12-31: -109707000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Operating Cash Flow: -109707000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109707000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1722225 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	USD 272,000 Exact value Exact value: 272000 USD 2023-01-01 – 2023-12-31: 272000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Capital Expenditure: 272000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 272000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1727223 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.	−USD 109.98 million Calculation and evidence -109707000 − 272000 USD Exact free cash flow: -109979000 USD 2023-01-01 – 2023-12-31: -109707000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 272000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SYROS PHARMACEUTICALS, INC. · 2023-12-31 SYROS PHARMACEUTICALS, INC. (edgar:1556263) Free cash flow: -109979000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1556263?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109707000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1722225 Filing: 000095017024036808 Input fundies:CapitalExpenditure: 272000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1556263/000095017024036808/syrs-20231231.htm#1727223 Filing: 000095017024036808 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

48 filings · 2,239 latest values · 2,239 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001556263, 1556263, SYRS, edgar:1556263

Also known as LS22, Inc., SYROS PHARMACEUTICALS, INC., SYROS PHARMACEUTICALS, INC., Syros Pharmaceuticals, Inc.

SYROS PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation